ATE463250T1 - Herstellung und verwendung sulfatierter oligosaccharide - Google Patents

Herstellung und verwendung sulfatierter oligosaccharide

Info

Publication number
ATE463250T1
ATE463250T1 AT96910861T AT96910861T ATE463250T1 AT E463250 T1 ATE463250 T1 AT E463250T1 AT 96910861 T AT96910861 T AT 96910861T AT 96910861 T AT96910861 T AT 96910861T AT E463250 T1 ATE463250 T1 AT E463250T1
Authority
AT
Austria
Prior art keywords
pct
production
date oct
sec
oligosaccharides
Prior art date
Application number
AT96910861T
Other languages
English (en)
Inventor
Christopher Parish
William Cowden
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3786969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE463250(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Australian filed Critical Univ Australian
Application granted granted Critical
Publication of ATE463250T1 publication Critical patent/ATE463250T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
AT96910861T 1995-04-28 1996-04-24 Herstellung und verwendung sulfatierter oligosaccharide ATE463250T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN2618A AUPN261895A0 (en) 1995-04-28 1995-04-28 Preparation and use of sulfated oligosaccharides
PCT/AU1996/000238 WO1996033726A1 (en) 1995-04-28 1996-04-24 Preparation and use of sulfated oligosaccharides

Publications (1)

Publication Number Publication Date
ATE463250T1 true ATE463250T1 (de) 2010-04-15

Family

ID=3786969

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910861T ATE463250T1 (de) 1995-04-28 1996-04-24 Herstellung und verwendung sulfatierter oligosaccharide

Country Status (26)

Country Link
US (1) US6143730A (de)
EP (1) EP0837683B1 (de)
JP (2) JP4514240B2 (de)
KR (1) KR100591960B1 (de)
CN (1) CN1090021C (de)
AT (1) ATE463250T1 (de)
AU (1) AUPN261895A0 (de)
BR (1) BR9608041B8 (de)
CA (1) CA2218872C (de)
CZ (1) CZ341097A3 (de)
DE (1) DE69638158D1 (de)
EA (1) EA001199B1 (de)
EE (1) EE9700277A (de)
ES (1) ES2341924T3 (de)
FI (1) FI974060A0 (de)
HU (1) HUP9802394A2 (de)
IL (1) IL118047A (de)
IS (1) IS4596A (de)
NO (1) NO974911L (de)
NZ (1) NZ305815A (de)
PL (1) PL184357B1 (de)
PT (1) PT837683E (de)
TR (1) TR199701264T1 (de)
TW (1) TW446710B (de)
WO (1) WO1996033726A1 (de)
ZA (1) ZA963339B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO556297A0 (en) * 1997-03-11 1997-04-10 Australian National University, The Sulfated oligosaccharides having anticoagulant/ antithrombotic activity
DE69815122T2 (de) * 1997-08-28 2003-12-24 University Of Washington, Seattle Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
AUPO888497A0 (en) * 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
AUPO976897A0 (en) * 1997-10-14 1997-11-06 Australian National University, The Use of sulfated oligosaccharides in lowering blood triglyceride levels
GB9802725D0 (en) * 1998-02-09 1998-04-08 Ciba Geigy Ag Organic compounds
US7081448B2 (en) * 1998-11-24 2006-07-25 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US7132402B2 (en) * 1998-11-24 2006-11-07 Wyeth Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB0001481D0 (en) * 2000-01-21 2000-03-15 Theryte Ltd System for delivering a medicament
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
FR2808687B1 (fr) * 2000-04-27 2003-12-05 Goemar Lab Sa Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
JP4676048B2 (ja) * 2000-07-10 2011-04-27 生化学工業株式会社 脱髄性疾患処置剤
US7407773B2 (en) * 2000-11-03 2008-08-05 Procognia, Ltd. Method for characterizing a carbohydrate polymer
TW519716B (en) * 2000-12-19 2003-02-01 Tokyo Electron Ltd Wafer bias drive for a plasma source
CA2435637A1 (en) * 2001-01-23 2002-08-01 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
CN1394867A (zh) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
EP1427427B1 (de) 2001-09-12 2011-06-08 SIGMA-TAU Research Switzerland S.A. Derivate von teildesulfatierten glycosaminoglycanen als inhibitoren von heparanase, mit antiangiogener wirkung und ohne antikoagulatorische wirkung
KR20030046810A (ko) * 2001-12-06 2003-06-18 은삼제약 주식회사 콘드로이친 황산의 분해산물을 포함하는 관절염 예방 또는치료용 약학적 조성물
AUPS052802A0 (en) * 2002-02-15 2002-03-07 Praxis Pharmaceuticals International Pty Ltd Carbohydrate-based anti-wrinkle and tissue remodelling compounds
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
US20040161476A1 (en) * 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
MXPA06010049A (es) * 2004-03-04 2007-04-10 Progen Ind Ltd Derivados de oligosacaridos sulfatados.
CA2666840C (en) * 2006-10-20 2015-07-14 The Australian National University Inhibition of degradation of extracellular matrix
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
DK2164501T3 (en) * 2007-05-31 2016-05-30 Paradigm Biopharmaceuticals Ltd Sulfated xylans for the treatment or prophylaxis of respiratory diseases
FR2917971B1 (fr) 2007-06-28 2009-10-23 Engelhard Lyon Soc Par Actions Composition amincissante
WO2009000935A1 (en) * 2007-06-28 2008-12-31 Basf Beauty Care Solutions France Sas Slimming composition
US8153611B2 (en) * 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
EP2205616B3 (de) 2007-10-16 2020-01-22 Progen PG500 Series Pty Ltd. Neue sulfatierte oligosaccharidderivate
WO2009078015A2 (en) * 2007-12-18 2009-06-25 Procognia (Israel) Ltd Method and assay for glycosylation pattern detection related to cell state of stem cells
JP2011522805A (ja) * 2008-05-30 2011-08-04 モメンタ ファーマシューティカルズ インコーポレイテッド 糖構造ならびにそのような構造を作製および使用する方法
EP2149580A1 (de) 2008-07-15 2010-02-03 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Mimetika aus sulfatierten Oligosacchariden
US9029530B2 (en) * 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US8592140B2 (en) 2009-01-02 2013-11-26 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
GB0915315D0 (en) * 2009-09-03 2009-10-07 Univ Manchester Use of non-digestible oligosaccharides
JP5701498B2 (ja) * 2009-12-01 2015-04-15 公益財団法人微生物化学研究会 炎症性細胞からのヘパラナーゼの放出抑制剤、抗炎症剤、及び薬用組成物
ES2817779T3 (es) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluación de preparaciones de heparina
WO2011122321A1 (ja) * 2010-03-29 2011-10-06 国立大学法人名古屋大学 ヘパリン結合性蛋白に対する生理活性阻害剤
US9226939B2 (en) * 2010-12-01 2016-01-05 The Australian National University Histone inhibition
EP2675895A4 (de) * 2011-02-18 2014-07-30 Harvard College Molekularer schalter für neuronales wachstum
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102199175A (zh) * 2011-04-07 2011-09-28 福州大学 硫酸类肝素二糖的制备纯化方法及其纯化产品
EP2722049A4 (de) * 2011-06-09 2014-12-10 Medigen Biotechnology Corp Pharmazeutische zusammensetzung zur hemmung von rezidiv, verschlimmerung und metastasen eines leberkarzinoms
US20130209444A1 (en) * 2012-01-30 2013-08-15 Baxter Healthcare S.A. Non-anticoagulant sulfated or sulfonated polysaccharides
BR112015028710A2 (pt) * 2013-05-16 2017-09-19 Agency Science Tech & Res Sulfato de heparan hs8 isolado ou substancialmente purificado, composição farmacêutica ou medicamento, implante biocompatível ou prótese, método de formação de um implante ou prótese biocompatível, método de cultivo de células-tronco, método de enriquecimento para unidades formadoras de colônias, meio de cultura, kit de peças, produtos e método para aumentar a estabilidade de um fator de crescimento
JP2017515898A (ja) 2014-05-08 2017-06-15 イミューンエクサイト， インコーポレイテッド 免疫調節β−１，６−Ｄ−グルカン
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
CZ306662B6 (cs) * 2015-06-26 2017-04-26 Contipro A.S. Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
JP2016199579A (ja) * 2016-07-08 2016-12-01 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
CN110291073A (zh) 2016-12-13 2019-09-27 贝塔医疗私人有限公司 乙酰肝素酶抑制剂及其用途
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US11141428B2 (en) * 2017-12-12 2021-10-12 Academia Sinica Octasaccharides and uses thereof
WO2019113646A1 (en) * 2017-12-15 2019-06-20 Griffith University Sulfation method
JP6619830B2 (ja) * 2018-02-22 2019-12-11 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
NL2024493B1 (en) * 2019-12-16 2021-09-02 Logick Energetics B V Pharmaceutical composition for preventing or stopping metastases
CN114828846B (zh) 2019-12-18 2025-04-18 罗吉科能量有限公司 用于预防或阻止转移的医药组合物
CN110917208B (zh) * 2019-12-27 2021-02-12 浙江医院 硫酸化甘露葡萄糖醛酸六糖在防治动脉粥样硬化中的应用
CN111904968A (zh) * 2020-08-21 2020-11-10 青岛市中心医院 硫酸半乳四糖及其衍生物在制备抗上皮细胞黏附药物中的应用
CN113633658A (zh) * 2021-07-09 2021-11-12 南京理工大学 硫酸葡半乳寡聚糖在制备抗凝血和/或抗血栓药物中的应用
CN114134188B (zh) * 2021-07-23 2023-03-17 光明乳业股份有限公司 一种发酵小麦麸皮合成胞外多糖的方法
CN115646378A (zh) * 2022-09-15 2023-01-31 哈尔滨工业大学 一种生物质胶质凝胶及其制备方法、应用
CN116650425B (zh) * 2023-07-13 2025-06-27 晟迪生物医药(苏州)有限公司 糖酯化合物或其盐在冷冻保护、冷冻干燥保护中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869530B (en) * 1985-12-24 1987-10-28 Marion Laboratories Inc Use of synthetic sulfated saccharides to enhance wound healing
FR2597484B1 (fr) * 1986-04-17 1988-12-23 Sanofi Sa Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.
US5541166A (en) * 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
EP0338092A1 (de) * 1987-10-30 1989-10-25 Chugai Seiyaku Kabushiki Kaisha Anti-hiv-agens
US5506210A (en) * 1988-08-19 1996-04-09 The Australian National University Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
JPH0296588A (ja) * 1988-09-29 1990-04-09 Rikagaku Kenkyusho 硫酸化オリゴ糖及びその関連物質
JP2956090B2 (ja) * 1989-10-30 1999-10-04 大日本インキ化学工業株式会社 オリゴ糖誘導体
EP0497988A4 (en) * 1990-08-23 1993-03-10 Dainippon Ink And Chemicals, Inc. Antiviral agent
CA2061370A1 (en) * 1991-03-13 1992-09-14 Markus Hosang Pharmaceutical preparations
JPH06506973A (ja) * 1991-04-17 1994-08-04 グライコメッド　インコーポレイテッド 平滑筋細胞増殖のインヒビターとしての硫酸化多糖類
JPH06256373A (ja) * 1993-01-11 1994-09-13 Dainippon Ink & Chem Inc 硫酸化オリゴ糖配糖体アシル化物およびこれを有効成分とする抗ウイルス剤
US5459257A (en) * 1993-01-11 1995-10-17 Dainippon Ink And Chemicals, Inc. Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient
FR2710741B1 (fr) * 1993-09-30 1995-10-27 Commissariat Energie Atomique Capteur électronique destiné à la caractérisation de grandeurs physiques et procédé de réalisation d'un tel capteur.
JPH09503510A (ja) * 1993-10-07 1997-04-08 グリコメド・インコーポレイテッド ヘパリン様特性を有する高硫酸化マルトオリゴ糖
US5739115A (en) * 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties

Also Published As

Publication number Publication date
NZ305815A (en) 1999-05-28
JP4514240B2 (ja) 2010-07-28
EE9700277A (et) 1998-04-15
NO974911L (no) 1997-12-29
ES2341924T3 (es) 2010-06-29
PL184357B1 (pl) 2002-10-31
HUP9802394A2 (hu) 1999-02-01
JP2009235085A (ja) 2009-10-15
FI974060L (fi) 1997-10-27
EA199700347A1 (ru) 1998-06-25
IS4596A (is) 1997-10-21
EP0837683A1 (de) 1998-04-29
KR100591960B1 (ko) 2007-12-04
FI974060A7 (fi) 1997-10-27
CN1183043A (zh) 1998-05-27
MX9708289A (es) 1998-06-30
US6143730A (en) 2000-11-07
NO974911D0 (no) 1997-10-24
FI974060A0 (fi) 1997-10-27
BR9608041B1 (pt) 2012-02-22
KR19990008198A (ko) 1999-01-25
IL118047A (en) 2000-11-21
WO1996033726A1 (en) 1996-10-31
CA2218872A1 (en) 1996-10-31
BR9608041B8 (pt) 2014-11-18
ZA963339B (en) 1997-01-03
EA001199B1 (ru) 2000-12-25
PT837683E (pt) 2010-07-09
EP0837683A4 (de) 2007-07-04
AUPN261895A0 (en) 1995-05-18
CA2218872C (en) 2007-02-20
TR199701264T1 (xx) 1998-02-21
JPH11504018A (ja) 1999-04-06
CZ341097A3 (cs) 1998-03-18
BR9608041A (pt) 1999-01-26
CN1090021C (zh) 2002-09-04
IL118047A0 (en) 1996-08-04
EP0837683B1 (de) 2010-04-07
PL323080A1 (en) 1998-03-02
DE69638158D1 (de) 2010-05-20
TW446710B (en) 2001-07-21

Similar Documents

Publication Publication Date Title
ATE463250T1 (de) Herstellung und verwendung sulfatierter oligosaccharide
DK0696297T3 (da) Pyridobisimidazolbaseret stiv stavpolymer
BR9909325A (pt) Composições de poliuretano não elastomérico
FI910857A0 (fi) Foerfarande foer framstaellning av oxetanoner.
ATE193883T1 (de) Verbindungen und ihre zusammensetzungen mit entzündungshemmenden und anti-thrombotischen wirkungen
BG103485A (en) Ketobanzamides as calpain inhibitors
ATE197713T1 (de) Einkomponenten anorganische-organische netzwerk- materialien sowie deren vorläufer
NO970495D0 (no) Aryltioforbindelser som anti-bakterielle og antivirale midler
BR0213063A (pt) Antibióticos de ação dupla
TR200100672T2 (tr) Yeni izoksazolinon antibakteriyel ajanları
DK0447171T3 (da) Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf
DK1077218T3 (da) Peptidomimetiske forbindelser omfattende RGD-sekvenser, som er nyttige som integrininhibitorer
NO953281D0 (no) Anvendelse av oligosakkaridglykosider som hemmere av bakteriell adherens
BRPI0412744A (pt) derivados de combretastatina com ação citotóxica
DE69703796D1 (de) N-bis- oder n-tris-[(1,2-dicarboxy-ethoxy)-ethyl]-amin-derivate und herstellung und anwendung derselben
NO971318L (no) Jodiserte röntgenkontrastmidler
TR199800210T2 (xx) Didepsipeptid temelli endoparazitisid kompozisyonlar, yeni didepsipeptidler ve bunlar�n �retimi i�in i�lemler.
TR200400907T4 (tr) Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları
ZA983231B (en) Substituted benzyloxyimino compounds.
ATE7700T1 (de) 2-hydroxy-1,2,4-butantricarbonsaeure-oligoribosi - derivate, verfahren zu ihrer herstellung und ihre verwendung als prophylaktische mittel gegen zahnkaries.
GB9806358D0 (en) Synthesis of carboxylic acid derivatives
DE59606435D1 (de) 17-difluormethylen-estratriene
BR9407232A (pt) Compostos de tiocarbamoíla
ATE263560T1 (de) Neue verwendung von citreamicinen
AU2148899A (en) 15-methyl-cyclopropanosteroids and method for the production thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties